Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Strong Growth 2030 At 20.2% CAGR

The Business Research Company

The Business Research Company’s Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Global Market Report 2026 –Market Size 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, September 3, 2026 /EINPresswire.com/ -- The rapid advancement of artificial intelligence (AI) is transforming many sectors, and the field of drug safety and pharmacovigilance is no exception. AI-driven platforms are revolutionizing how adverse drug reactions are detected and managed, promising to enhance patient safety and streamline regulatory compliance. Below, we explore the current market size, growth drivers, key regional trends, and the innovative technologies shaping this evolving industry.

Market Overview and Growth Forecast of the AI-Driven Drug Safety and Pharmacovigilance Platforms
The AI-driven drug safety and pharmacovigilance platforms market has experienced remarkable expansion in recent years. It is projected to grow from $2.14 billion in 2025 to $2.59 billion in 2026, reflecting a strong compound annual growth rate (CAGR) of 20.6%. This surge is largely due to increasing global mandates on adverse drug reaction reporting, the digitization of clinical trial information, expanding pharmacovigilance regulations, heightened pharmaceutical research activities, and broader adoption of electronic health records across healthcare systems.

Download a free sample of the artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms market report:
https://thebusinessresearchcompany.com/sample_request?id=14702596&type=smp&name=Artificial%20Intelligence%20%28AI%29-Driven%20Drug%20Safety%20And%20Pharmacovigilance%20Platforms%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Sep_PR

Looking toward the future, the market is expected to continue its accelerated trajectory, reaching a valuation of $5.39 billion by 2030 with a CAGR of 20.2%. The anticipated growth drivers include the integration of AI technologies within drug safety monitoring systems, wider use of real-world evidence in pharmacovigilance, stricter regulatory requirements for automated compliance reporting, advances in predictive safety analytics platforms, and the growing implementation of cloud-based drug safety monitoring solutions. Emerging market trends highlight the adoption of AI-powered adverse event detection, natural language processing for safety signal extraction, predictive analytics platforms for pharmacovigilance, real-time drug safety monitoring using real-world data, and automated systems for regulatory safety reporting.

Understanding AI-Driven Drug Safety and Pharmacovigilance Platforms
Artificial intelligence-powered drug safety and pharmacovigilance platforms utilize software technologies such as machine learning, natural language processing, and advanced data analytics to monitor, evaluate, and prevent adverse drug reactions and safety risks related to pharmaceutical products. These platforms analyze vast amounts of clinical, real-world, and regulatory data to enhance the detection of safety signals, automate the process of safety reporting, and ensure compliance with regulatory requirements throughout the pharmaceutical product lifecycle.

View the full artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms market report:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-drug-safety-and-pharmacovigilance-platforms-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Sep_PR

Rising Adverse Event Reports Fuel Market Demand
A significant factor propelling growth in the AI-driven drug safety and pharmacovigilance platforms market is the increasing number of adverse event (AE) reports. These reports document unintended and harmful effects experienced following drug use. Stricter regulatory mandates require healthcare professionals and pharmaceutical companies to report more comprehensive safety information more frequently. AI-driven platforms aggregate AE data from clinical systems, electronic health records, and real-world sources to identify and categorize safety signals, expedite case processing, and enhance the speed and accuracy of regulatory decisions. For example, in February 2024, the Department of Health Abu Dhabi reported a total of 1,522 adverse drug reaction reports submitted in 2023, marking a 235% increase compared to previous years. This surge clearly illustrates how rising AE reports are driving demand for AI-based pharmacovigilance solutions.

Regulatory Frameworks and Digitization Support Market Growth
The expansion of regulatory frameworks governing drug safety and the digital transformation of health data have also been key growth engines. Increasing digitization enables more efficient collection and analysis of pharmacovigilance data, making AI-powered platforms indispensable tools for regulatory compliance and patient safety enhancement. The growing emphasis on real-world evidence and predictive analytics further strengthens the case for adopting AI technologies in this sector.

Regional Insights and Market Expansion Patterns
In 2025, North America held the largest share of the AI-driven drug safety and pharmacovigilance platforms market. However, the Asia-Pacific region is forecasted to experience the fastest growth over the coming years. The market overview also covers important geographic markets including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering an extensive perspective on global developments and emerging opportunities within this space.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X